Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.

ABSTRACT:

Introduction

Glial fibrillary acidic protein (GFAP) may contribute to Alzheimer's pathology at early disease stages. GFAP moderation of Alzheimer's disease (AD)-related neurodegeneration and cognition is unclear.

Methods

We examined plasma GFAP moderation of AD biomarkers (amyloid beta [Aβ]-positron emission tomography [PET][A]; plasma phosphorylated tau-181 [p-tau181][T₁]), neurodegeneration (plasma NfL[N_plasma]; structural magnetic resonance imaging [MRI][N_MRI]), and cognition (Cog_memory; Cog_executive) in two cohorts: University of California San Francisco (UCSF) (N = 212, 91.0% non-Hispanic/Latino White [NHLW], age = 74.7 [7.6] years, 75.9% cognitively unimpaired [CU]) and 1Florida Alzheimer's Disease Research Centers

SUBMITTER: Lee SY 

PROVIDER: S-EPMC12412752 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature